BioWorld Asia

Jan. 5, 2005

Neuro3d's Third Round: EUR31.5M For Development Of Lead Drugs

PARIS - Neuro3d closed a third round of financing in which it raised €31.5 million (US$41.6 million) from eight European venture capital funds. (BioWorld International) Read More

Arrow Spins Out Immunoprime To Focus On Infectious Disease

New Study Highlights Cell Cycle Regulation Intricacy

BioAlliance Pharma To File In EU For Miconazole Lauriad Approval

Stem Cell Foundation Planned To Help Bridge UK Funding Gap

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 31, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 31, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...

Big pharma taps fast Asia innovation in search of next Keytruda

BioWorld

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...